OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Child & Adolescent Health is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Eliminating hepatitis B: the ball is in our court	260
Which children in the USA have access to heroic salvage therapy?	190
Primaquine for children, once and for all	183
The case for action in paediatric neuromodulation – Author's reply	137
Gamblification: risks of digital gambling games to adolescents	128
The health and wellbeing case for children's suffrage	117
Child poverty in 2023: inequity in times of crises	115
Paediatric group A streptococcal disease in England: a primary care perspective	112
The WHO Model List of Essential Medicines for Children needs its own identity: the case of psychotropic medicines	107
Preventing reproductive coercion in adolescence	106
Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomis	104
Tackling post-discharge mortality in children living in LMICs to reduce child deaths	103
Tackling childhood cancer in sub-Saharan Africa	85
Correction to Lancet Child Adolesc Health 2024; 8: 482–90	84
Thank you to The Lancet Child & Adolescent Health statistical and peer reviewers in 2025	81
Correction to Lancet Child Adolesc Health 2026; 10: 103–10	81
Early fetal intervention: balancing technological breakthroughs and long-term morbidity	80
Obesity-related asthma in children and adolescents	79
Global prevalence of hypertension among children and adolescents aged 19 years or younger: an updated systematic review and meta-analysis	76
Current treatment outcomes of congenital heart disease and future perspectives	72
Medically cleared and waiting for healing to begin	71
Effect of the COVID-19 pandemic on adolescent mental health and substance use up to March, 2022, in Iceland: a repeated, cross-sectional, population-based study	71
Adolescents and the International Conference on Population and Development at 30	68
Self-asphyxial behaviour in adolescents	66
Trajectories of airflow limitation from childhood to early adulthood: an analysis of six population-based birth cohorts	66

New fellows of the UK Academy of Medical Sciences	65
Just getting bi?	64
A spotlight on Streetlights Uganda	63
Social determinants, inequality, and autism	63
Toward climate-smart, mental health-safe schools	61
Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands	58
Correction to Lancet Child Adolesc Health 2023; 7: 684–85	58
Longitudinal association between dysmenorrhoea in adolescence and chronic pain in adulthood: a UK population-based study	57
Rare and severe adverse events in children with inflammatory bowel disease: analysis of data from the PIBD-SETQuality Safety Registry	56
Correction to Lancet Child Adolesc Health 2025; 9: 837–47	56
Pathological demand avoidance: further research is required – Authors' reply	55
Adolescent girls at the intersection of poverty, migration, and gender	55
The healing powers of music	53
“As we grieved, we grew”	51
Thank you to The Lancet Child & Adolescent Health's statistical and peer reviewers in 2023	51
Coping with and challenging the impacts of COVID-19	50
When vaccine adverse event reporting generates hope, not fear	48
Ethical and legal considerations in the care of children and young people with high consequence infectious diseases (HCIDs): an approach to decision making	48
Trust, but verify: a new potential association between food allergy and asthma in children	48
Recognising context and power in youth mental health	47
Neonatal research outcomes: the ethical imperative to change attitudes	47
Efficacy and safety of methylphenidate and behavioural parent training for children aged 3–5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sh	46
Investing in childhood cancer registries to drive progress	46
Caring for children with cancer evacuated from Ukraine	46